Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $12.9 million.

  • Exagen's Total Current Liabilities rose 4686.11% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 4686.11%. This contributed to the annual value of $13.5 million for FY2024, which is 1347.67% up from last year.
  • Per Exagen's latest filing, its Total Current Liabilities stood at $12.9 million for Q3 2025, which was up 4686.11% from $10.3 million recorded in Q2 2025.
  • Exagen's 5-year Total Current Liabilities high stood at $14.0 million for Q1 2025, and its period low was $7.9 million during Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $9.6 million (2022), whereas its average is $10.2 million.
  • As far as peak fluctuations go, Exagen's Total Current Liabilities plummeted by 2201.28% in 2023, and later surged by 5934.19% in 2025.
  • Over the past 5 years, Exagen's Total Current Liabilities (Quarter) stood at $9.3 million in 2021, then grew by 3.27% to $9.6 million in 2022, then rose by 23.68% to $11.9 million in 2023, then grew by 13.48% to $13.5 million in 2024, then fell by 4.56% to $12.9 million in 2025.
  • Its Total Current Liabilities stands at $12.9 million for Q3 2025, versus $10.3 million for Q2 2025 and $14.0 million for Q1 2025.